BCM
RGLS

Bridgeway Capital Management’s Regulus Therapeutics RGLS Stock Holding History

Bridgeway Capital Management’s Portfolio RGLS Stock Details RGLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-333
Closed -$66K – 1463
2017
Q1 		$66K Sell
333
-1,799
-84% -$342K ﹤0.01% 1355
2016
Q4 		$576K Hold
2,132
– – 0.01% 1036
2016
Q3 		$844K Buy
+2,132
New +$877K 0.01% 873
2016
Q1 		– Sell
-417
Closed -$436K – 1476
2015
Q4 		$436K Hold
417
– – 0.01% 1103
2015
Q3 		$327K Hold
417
– – 0.01% 1188
2015
Q2 		$548K Hold
417
– – 0.01% 1035
2015
Q1 		$847K Hold
417
– – 0.02% 860
2014
Q4 		$802K Buy
+417
New +$742K 0.02% 859

Other funds holding RGLS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SDIC
South Dakota Investment Council Sioux Falls, South Dakota $5.24B AUM 22.1% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
RPAM
Rhenman & Partners Asset Management Stockholm, Sweden $810M AUM 30.2% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bridgeway Capital Management's RGLS Position: Q2 2017 in Review

Bridgeway Capital Management sold out of Regulus Therapeutics (RGLS) in Q2 2017, closing a stake of 333 shares — an estimated $66K sold.

Bridgeway Capital Management first reported a position in RGLS in Q4 2014 and held it in 8 quarters. The position peaked at $847K in Q1 2015. 46 funds tracked by Wall St. Rank hold RGLS as of Q2 2017.

  • Bridgeway Capital Management reported no remaining Regulus Therapeutics position as of Q2 2017 after selling out during the quarter.
  • Bridgeway Capital Management sold 333 Regulus Therapeutics shares in Q2 2017, an estimated $66K.
  • Bridgeway Capital Management first reported a position in Regulus Therapeutics in Q4 2014 and held it in 8 quarters.
  • Bridgeway Capital Management's Regulus Therapeutics position peaked at $847K in Q1 2015.
  • 46 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q2 2017.

Based on Bridgeway Capital Management's 13F filing for Q2 2017, filed 14 Aug 2017.